Clinical Trials Logo

Dermatitis, Atopic clinical trials

View clinical trials related to Dermatitis, Atopic.

Filter by:

NCT ID: NCT00438022 Completed - Atopic Dermatitis Clinical Trials

Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis

Start date: March 2006
Phase: N/A
Study type: Observational

Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema. Eczema herpeticum (EH) is a type of eczema that spreads due to an underlying herpes virus infection. The purpose of this research study is to identify the risk factors that may cause EH.

NCT ID: NCT00419406 Completed - Atopic Dermatitis Clinical Trials

Medium-Dose UVA1 Versus Narrow-Band UVB in Atopic Dermatitis

Start date: March 2005
Phase: N/A
Study type: Interventional

Atopic dermatitis (AD) is a very common disorder that is characterized by pruritic inflammatory skin lesions, with patients usually having an individual or family history of atopic diseases in their background. Phototherapy is among the first-line approaches in the management of AD. In this context, a variety of studies have shown a beneficial effect of natural or artificial UV radiation in atopic dermatitis (AD). The past ten years have seen the introduction of new phototherapeutic regimens for AD, including UVA1 and NB-UVB.UVA1 seems to be more effective than the above mentioned broadband spectra, in particular in acute severe AD. The aim of the present study is the comparison of UVA1 and NB-UVB phototherapy in the treatment of AD. Additionally, the course of several cytokines, human beta-defensins, and SMAD-proteins will be evaluated during the course of treatment.

NCT ID: NCT00407979 Completed - Psoriasis Clinical Trials

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

Start date: July 2005
Phase: N/A
Study type: Observational

Cathelicidins are small proteins in the human body that protect against infection. The purpose of this study is to determine if the amount of cathelicidins and other small proteins found in saliva can predict the amount of these in the skin of people who have acute atopic dermatitis (AD) or psoriasis.

NCT ID: NCT00407069 Completed - Atopic Dermatitis Clinical Trials

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

Start date: June 2005
Phase: N/A
Study type: Observational

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.

NCT ID: NCT00406081 Completed - Atopic Dermatitis Clinical Trials

Immune Response to Varicella Vaccination in Children With Atopic Dermatitis

Start date: December 2005
Phase: N/A
Study type: Observational

Atopic dermatitis (AD) causes people to be susceptible to skin infection and inflammations. The purpose of this study is to determine the immune response to chicken pox vaccine in children with or without AD who received the vaccine 2 to 16 weeks prior to the study visit.

NCT ID: NCT00392067 Completed - Atopic Dermatitis Clinical Trials

LEO19123 Cream in the Treatment of Atopic Dermatitis

Start date: October 2006
Phase: Phase 2
Study type: Interventional

To compare the efficacy and safety of two different dose combinations of LEO19123 (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of patients with atopic dermatitis

NCT ID: NCT00379678 Completed - Atopic Dermatitis Clinical Trials

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

Start date: September 2006
Phase: N/A
Study type: Observational

THe study seeks to determine if pimecrolimus has a positive effect on increasing antimicrobial peptide expression and reducing vaccinia virus growth in the skin explants from patients with atopic dermatitis.

NCT ID: NCT00376129 Completed - Atopic Dermatitis Clinical Trials

Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis

Start date: January 2006
Phase: Phase 2
Study type: Interventional

Protocol Title: Open-label,single center study to evaluate the savety and efficacy of an intramuscular 12 week-course of Alefacept in patients with atopic dermatitis. Study Phase: II Study Design: Open-label, single center Primary Study Objective: to determine the safety and efficacy of one course of Alefasept when administered as a 15 mg intramuscular ( IM) injektion to patients with atopic dermatitis Secondary Study Objective: to investigate key immunological parameters involved in the pathology of this common skin disease to interpret the clinical findings Number of patients: 10 Study Population: Male and female patients, at least 18 years of age with atopic dermatitis, aktive inflammation, a severity score of 6-9 according to Langeland and Rajika and an EASI of >20 Treatment Groups: Alefacept will be administered as a 15 mg IM injection once a week for 12 weeks, followed by a 12-week follow-up period.

NCT ID: NCT00371163 Completed - Psoriasis Clinical Trials

Molecular and Cellular Characterization of Spongiotic Dermatitis

Spongiotic
Start date: September 2006
Phase: N/A
Study type: Observational

Spongiotic dermatitis is the histopathologic diagnosis commonly issued by dermatopathologists that encompasses atopic dermatitis, contact dermatitis, and other forms of eczematous dermatitis. The information obtained will assist in development of diagnostic methods for differentiation of the types of spongiotic dermatitis. This study also has the potential to lead to the dissection of pathologic pathways involved in these diseases and development of novel therapeutic agents.

NCT ID: NCT00367393 Completed - Atopic Dermatitis Clinical Trials

Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis

Start date: March 2006
Phase: Phase 4
Study type: Interventional

Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.